




<b>HUMANARZNEIMITTEL - EMA</b>	<b>2</b>
<i>Allgemeines – General</i>	2
<i>Pharmakovigilanz – PRAC</i>	2
<i>Zulassung – Regulatory Affairs</i>	3
<i>Orphan Drugs und neuartige Therapierichtungen (ATMP)</i>	4
<i>Qualität – Quality</i>	5
<i>(Prä-) Klinische Forschung – Research and Development</i>	5
<i>Kinderarzneimittel – Paediatrics</i>	5
<i>Pflanzliche Arzneimittel – Herbal medicines</i>	5
<b>EUROPEAN COMMISSION</b>	<b>7</b>
<b>EDQM</b>	<b>8</b>
<b>MEDIZINPRODUKTE</b>	<b>9</b>
<b>CMDH</b>	<b>10</b>
<b>HUMANARZNEIMITTEL - DEUTSCHLAND</b>	<b>11</b>
<b>HUMANARZNEIMITTEL - ÖSTERREICH</b>	<b>13</b>
<b>HUMANARZNEIMITTEL - SCHWEIZ</b>	<b>14</b>
 <b>FRAGEN AN DAS NETZWERK</b>	<b>15</b>
<b>VERANSTALTUNGEN / EVENTS – BEHÖRDEN UND ANDERE VERANSTALTER</b>	<b>16</b>
DEUTSCHLAND	16
ÖSTERREICH	16
SCHWEIZ	16
EUROPA	16
<u><a href="#">Urheberrechtshinweis:</a></u>	

Der MEGRA Newsletter und die darin enthaltenen Beiträge sind urheberrechtlich geschützt. Ohne die ausdrückliche Genehmigung der Urheber oder der Inhaber der Nutzungsrechte darf weder der MEGRA Newsletter noch Teile davon verbreitet, bearbeitet, öffentlich zugänglich, vorgetragen, in einem Abrufsystem gespeichert oder in ein solches eingeführt oder in einer beliebigen anderen Form (elektronisch, mechanisch, per Hyperlink, per Fotokopie, per Aufzeichnung oder auf anderem Wege) oder zu einem beliebigen anderen Zweck vervielfältigt oder übermittelt werden. Downloads und Kopien des Newsletters sind nur Mitgliedern der *Mittel Europäischen Gesellschaft für Regulatory Affairs e.V. (MEGRA)* und für den privaten, nicht kommerziellen Gebrauch gestattet. Durch das Herunterladen oder Kopieren von Inhalten werden keine Rechte bezüglich der Inhalte übertragen.

## Allgemeines – General

### **Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (26 June 2024) – Minutes for the meetings held available**

**Published on:** 13 - September - 2024

**For more information, please refer to:**

<https://www.ema.europa.eu/en/about-us/what-we-do/crisis-preparedness-management/executive-steering-group-shortages-medicinal-products/executive-steering-group-shortages-safety-medicinal-products-mssg-meetings>

### **Supporting innovation (updated)**

**Published on:** 18 - September - 2024

**For more information, please refer to:**

<https://www.ema.europa.eu/en/human-regulatory-overview/research-development/supporting-innovation>

### **SME Regulation and reports (updated)**

**Published on:** 18 - September - 2024

**For more information, please refer to:**

<https://www.ema.europa.eu/en/about-us/support-smes/sme-regulation-reports>

### **List of eligible industry stakeholder organisations (updated)**

**Published on:** 25 - September - 2024

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/other/list-eligible-industry-stakeholder-organisations\\_en.pdf](https://www.ema.europa.eu/en/documents/other/list-eligible-industry-stakeholder-organisations_en.pdf)

## Pharmakovigilanz – PRAC

### **Pharmacovigilance Risk Assessment Committee (PRAC) criteria to prioritise impact research (Rev.1) (updated)**

**Published on:** 17 - September - 2024

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/other/pharmacovigilance-risk-assessment-committee-prac-criteria-prioritise-impact-research-rev1\\_en.pdf](https://www.ema.europa.eu/en/documents/other/pharmacovigilance-risk-assessment-committee-prac-criteria-prioritise-impact-research-rev1_en.pdf)

### **Referral: Metamizole-containing medicinal products (updated)**

**Published on:** 20 - September - 2024

**For more information, please refer to:**

<https://www.ema.europa.eu/en/medicines/human/referrals/metamizole-containing-medicinal-products-0>

### **Referral: Oxbryta (updated)**

**Published on:** 26 - September - 2024

**For more information, please refer to:**

<https://www.ema.europa.eu/en/medicines/human/referrals/oxbryta>

## Humanarzneimittel - EMA

### **List of medicines under additional monitoring (updated)**

**Published on:** 25 - September - 2024

**For more information, please refer to:**

<https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/medicines-under-additional-monitoring/list-medicines-under-additional-monitoring>

### **List of European Union reference dates and frequency of submission of periodic safety update reports (PSURs) (updated)**

**Published on:** 25 - September - 2024

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/other/list-european-union-reference-dates-frequency-submission-periodic-safety-update-reports-psurs\\_en.xlsx](https://www.ema.europa.eu/en/documents/other/list-european-union-reference-dates-frequency-submission-periodic-safety-update-reports-psurs_en.xlsx)

### **MedDRA important medical event terms list - version 27.1**

**Published on:** 26 - September - 2024

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/other/27-1\\_ime\\_list.xlsx](https://www.ema.europa.eu/en/documents/other/27-1_ime_list.xlsx)

## Zulassung – Regulatory Affairs

### **EMA's human medicines committee elects new Chair**

**Published on:** 18 - September - 2024

**For more information, please refer to:**

<https://www.ema.europa.eu/en/news/emas-human-medicines-committee-elects-new-chair>

### **Environmental risk assessment of medicinal products for human use - Scientific guideline (updated)**

**Published on:** 12 - September - 2024

**For more information, please refer to:**

<https://www.ema.europa.eu/en/environmental-risk-assessment-medicinal-products-human-use-scientific-guideline>

### **Early dialogue with healthcare professional organisations for marketing authorisation applications: 1-year report**

**Published on:** 16 - September - 2024

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/report/early-dialogue-healthcare-professional-organisations-marketing-authorisation-applications-1-year-report\\_en.pdf](https://www.ema.europa.eu/en/documents/report/early-dialogue-healthcare-professional-organisations-marketing-authorisation-applications-1-year-report_en.pdf)

### **IRIS guide for applicants - How to create and submit scientific applications, for industry and individual applicants**

**Published on:** 16 - September - 2024

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/iris-guide-applicants\\_en.pdf](https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/iris-guide-applicants_en.pdf)

## Humanarzneimittel - EMA

**Establishing efficacy based on single-arm trials submitted as pivotal evidence in a marketing authorisation (updated)**

**Published on:** 16 - September - 2024

**For more information, please refer to:**

<https://www.ema.europa.eu/en/establishing-efficacy-based-single-arm-trials-submitted-pivotal-evidence-marketing-authorisation>

**Questions and answers on labelling requirements for centrally authorised metered dose inhalers containing fluorinated greenhouse gases**

**Published on:** 19 - September - 2024

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/other/questions-answers-labelling-requirements-centrally-authorized-metered-dose-inhalers-containing-fluorinated-greenhouse-gases\\_en.pdf](https://www.ema.europa.eu/en/documents/other/questions-answers-labelling-requirements-centrally-authorized-metered-dose-inhalers-containing-fluorinated-greenhouse-gases_en.pdf)

**QRD statements for metered dose inhalers containing fluorinated greenhouse gases**

**Published on:** 23 - September - 2024

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/other/qrd-statements-metered-dose-inhalers-containing-fluorinated-greenhouse-gases\\_en.pdf](https://www.ema.europa.eu/en/documents/other/qrd-statements-metered-dose-inhalers-containing-fluorinated-greenhouse-gases_en.pdf)

**List of centrally authorised products with safety-related changes to the product information (updated)**

**Published on:** 25 - September - 2024

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/list-centrally-authorized-products-safety-related-changes-product-information\\_en.xlsx](https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/list-centrally-authorized-products-safety-related-changes-product-information_en.xlsx)

### Orphan Drugs und neuartige Therapierichtungen (ATMP)

**New chair elected for EMA's Orphan Medicinal Products Committee**

**Published on:** 16 - September - 2024

**For more information, please refer to:**

<https://www.ema.europa.eu/en/news/new-chair-elected-emas-orphan-medicinal-products-committee>

**Information session on the pilot for expert panels' advice for orphan medical devices, Event - 23 - September - 2024 (updated)**

Video recording available

**Published on:** 27 - September - 2024

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/information-session-pilot-expert-panels-advice-orphan-medical-devices>

## Qualität – Quality

**Compilation of Union procedures on inspections and exchange of information (updated)**

**Published on:** 26 - September - 2024

**For more information, please refer to:**

<https://www.ema.europa.eu/en/human-regulatory-overview/research-development/compliance-research-development/good-manufacturing-practice/compilation-union-procedures-inspections-exchange-information>

## (Prä-) Klinische Forschung – Research and Development

**Clinical Trials Regulation (CTR) Collaborate Stakeholder meeting, supported by ACT EU, Event - 11 - September - 2024 (updated)**

Presentations and Video recording available

**Published on:** 20 - September - 2024

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/clinical-trials-regulation-ctr-collaborate-stakeholder-meeting-supported-act-eu>

**Clinical Trial Information System (CTIS) evaluation timelines (updated)**

**Published on:** 20 - September - 2024

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/other/clinical-trial-information-system-ctis-evaluation-timelines\\_en.pdf](https://www.ema.europa.eu/en/documents/other/clinical-trial-information-system-ctis-evaluation-timelines_en.pdf)

**CTIS newsflash - 24 September 2024**

**Published on:** 25 - September - 2024

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-24-september-2024\\_en.pdf](https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-24-september-2024_en.pdf)

## Kinderarzneimittel – Paediatrics

**No news published**

## Pflanzliche Arzneimittel – Herbal medicines

**Herbal medicinal product: Absinthii herba, F: Assessment finalised (updated)**

**Published on:** 18 - September - 2024

**For more information, please refer to:**

<https://www.ema.europa.eu/en/medicines/herbal/absinthii-herba>

**Herbal medicinal product: Rosmarini aetheroleum, F: Assessment finalised (updated)**

**Published on:** 20 - September - 2024

**For more information, please refer to:**

<https://www.ema.europa.eu/en/medicines/herbal/rosmarini-aetheroleum>

## Humanarzneimittel - EMA

**Herbal medicinal product: Rosmarini folium, F: Assessment finalised (updated)**

**Published on:** 26 - September - 2024

**For more information, please refer to:**

<https://www.ema.europa.eu/en/medicines/herbal/rosmarini-folium>

**Superseded community herbal monograph on Rosmarinus officinalis L., aetheroleum (updated)**

**Published on:** 20 - September - 2024

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-rosmarinus-officinalis-l-aetheroleum\\_en.pdf](https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-rosmarinus-officinalis-l-aetheroleum_en.pdf)

**Superseded community herbal monograph on Rosmarinus officinalis L., folium (updated)**

**Published on:** 26 - September - 2024

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-rosmarinus-officinalis-l-folium\\_en.pdf](https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-rosmarinus-officinalis-l-folium_en.pdf)

***Commission recommends stronger measures on smoke-free environments to better protect public health***

***Published on: 17 - September - 2024***

***For more information, please refer to:***

[https://ec.europa.eu/commission/presscorner/detail/en/IP\\_24\\_4682](https://ec.europa.eu/commission/presscorner/detail/en/IP_24_4682)

***Health Technology Assessment: Commission publishes new guidance on validity of clinical studies***

***Published on: 23 - September - 2024***

***For more information, please refer to:***

<https://ec.europa.eu/newsroom/sante/newsletter-archives/55866>

***Commission welcomes international declaration on the fight against antimicrobial resistance***

***Published on: 27 - September - 2024***

***For more information, please refer to:***

[https://ec.europa.eu/commission/presscorner/detail/en/IP\\_24\\_4847](https://ec.europa.eu/commission/presscorner/detail/en/IP_24_4847)

***Publication of two BSP studies on the BINACLE method – In vitro approach to safety testing of tetanus vaccines for human and veterinary use***

***Published on: 23 - September - 2024***

***For more information, please refer to:***

***<https://www.edqm.eu/en/-/publication-of-two-bsp-studies-on-the-binacle-method-in-vitro-approach-to-safety-testing-of-tetanus-vaccines-for-human-and-veterinary-use>***



## Medizinprodukte

***MDCG 2021-4 rev.1 - Application of transitional provisions for certification of class D in vitro diagnostic medical devices under Reg (EU) 2017/746 - September 2024***

***Published on: 23 - September - 2024***

***For more information, please refer to:***

***[https://health.ec.europa.eu/latest-updates/mdcg-2021-4-rev1-application-transitional-provisions-certification-class-d-vitro-diagnostic-medical-2024-09-25\\_en](https://health.ec.europa.eu/latest-updates/mdcg-2021-4-rev1-application-transitional-provisions-certification-class-d-vitro-diagnostic-medical-2024-09-25_en)***

***CMDh agenda and minutes (updated)***

***Published on:*** 23 - September - 2024

***For more information, please refer to:***

<https://www.hma.eu/human-medicines/cmdh/agendas-and-minutes.html>

***UPDATE - List of active substances for which data has been submitted in accordance with Article 45 of the Paediatric Regulation***

***Published on:*** 25 - September - 2024

***For more information, please refer to:***

<https://www.hma.eu/human-medicines/cmdh/paediatric-regulation/article-45-and-previous-worksharing.html>

***NEW - Art 45 PAR on Loperamide, loperamide/simethicone***

***Published on:*** 25 - September - 2024

***For more information, please refer to:***

<https://www.hma.eu/human-medicines/cmdh/paediatric-regulation/assessment-reports/article-45-work-sharing.html>

***UPDATE - Pharmacovigilance Legislation***

***Published on:*** 25 - September - 2024

***For more information, please refer to:***

<https://www.hma.eu/human-medicines/cmdh/questions-answers.html>

***UPDATE - Request for MRP/RUP / Update assessment report***

***Published on:*** 25 - September - 2024

***For more information, please refer to:***

<https://www.hma.eu/human-medicines/cmdh/templates/rup.html>

***Best Practice Guide for the exchange of regulatory and administrative information regarding orphan medicinal products between EMA and National Competent Authorities (modified)***

***Published on:*** 25 - September - 2024

***For more information, please refer to:***

<https://www.hma.eu/human-medicines/cmdh/procedural-guidance/general-info.html#c1772>

# Humanarzneimittel - Deutschland

## **Maßnahmen des BfArM und ergänzende Informationen zu Lieferengpässen**

**Veröffentlicht am:** 13 - September - 2024

**Weitere Informationen finden Sie unter:**

[https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Lieferengpaesse/Massnahmen-des-BfArM/\\_artikel.html?nn=986770](https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Lieferengpaesse/Massnahmen-des-BfArM/_artikel.html?nn=986770)

## **Informationen zu Rote-Hand-Briefen und Informationsbriefen**

**Veröffentlicht am:** 17 - September - 2024

**Weitere Informationen finden Sie unter:**

[https://www.bfarm.de/DE/Arzneimittel/Pharmakovigilanz/Risikoinformationen/Rote-Hand-Briefe/Zusatzinformationen/\\_artikel.html?nn=986770](https://www.bfarm.de/DE/Arzneimittel/Pharmakovigilanz/Risikoinformationen/Rote-Hand-Briefe/Zusatzinformationen/_artikel.html?nn=986770)

## **Muster: Dokumentation „Nicht Supervisory Authority Inspektion“**

**Veröffentlicht am:** 17 - September - 2024

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Pharmakovigilanz/Service/mitteil/muster-pharmakovigilanz-non-sa-inspektionen.html?nn=986770>

## **Muster: Dokumentation „Supervisory Authority Inspektion“**

**Veröffentlicht am:** 17 - September - 2024

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Pharmakovigilanz/Service/mitteil/muster-pharmakovigilanz-sa-inspektionen.html?nn=986770>

## **Klassifikationen: BfArM veröffentlicht endgültige Fassung der ICD-10-GM 2025**

**Veröffentlicht am:** 18 - September - 2024

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/SharedDocs/Pressemitteilungen/DE/2024/pm04-2024.html?nn=986770>

## **Versagungen und Rücknahmen BfArM Januar-August 2024**

**Veröffentlicht am:** 18 - September - 2024

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/SharedDocs/Downloads/DE/Service/Statistik/AM-Statistik/versagungen-2024.html?nn=986770>

## **COMP Ausschuss für Arzneimittel für seltene Leiden**

**Veröffentlicht am:** 18 - September - 2024

**Weitere Informationen finden Sie unter:**

[https://www.bfarm.de/DE/Das-BfArM/EU-und-Internationales/COMP-Ausschuss/\\_artikel.html?nn=986770](https://www.bfarm.de/DE/Das-BfArM/EU-und-Internationales/COMP-Ausschuss/_artikel.html?nn=986770)

## **Statistiken**

**Veröffentlicht am:** 18 - September - 2024

**Weitere Informationen finden Sie unter:**

[https://www.bfarm.de/DE/Aktuelles/Statistiken/\\_artikel.html?nn=986770](https://www.bfarm.de/DE/Aktuelles/Statistiken/_artikel.html?nn=986770)

## Humanarzneimittel - Deutschland

### **Meldeverpflichtungen**

**Veröffentlicht am:** 24 - September - 2024

**Weitere Informationen finden Sie unter:**

[https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Lieferengpaesse/Meldeverpflichtungen/\\_artikel.html?nn=986770](https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Lieferengpaesse/Meldeverpflichtungen/_artikel.html?nn=986770)

# Humanarzneimittel - Österreich

**PSUR outcome: Salicylsäure (topische Anwendung)**

**Veröffentlicht am:** 13 - September - 2024

**Weitere Informationen finden Sie unter:**

[https://www.basq.gv.at/fileadmin/redakteure/07\\_Unternehmen/PV-Mustertexte/ab\\_2023/240913\\_CL\\_PSUSA\\_Salicyls%C3%A4ure\\_signiert.pdf](https://www.basq.gv.at/fileadmin/redakteure/07_Unternehmen/PV-Mustertexte/ab_2023/240913_CL_PSUSA_Salicyls%C3%A4ure_signiert.pdf)

[Link zur Website der EMA](#)

**PSUR outcome: Dydrogesteron/Estradiol**

**Veröffentlicht am:** 13 - September - 2024

**Weitere Informationen finden Sie unter:**

[https://www.basq.gv.at/fileadmin/redakteure/07\\_Unternehmen/PV-Mustertexte/ab\\_2023/240913\\_CL\\_PSUSA\\_Dydrogesteron\\_Estradiol\\_sign.pdf](https://www.basq.gv.at/fileadmin/redakteure/07_Unternehmen/PV-Mustertexte/ab_2023/240913_CL_PSUSA_Dydrogesteron_Estradiol_sign.pdf)

[Link zur Website der EMA](#)

**PSUR outcome: Codein/Ibuprofen**

**Veröffentlicht am:** 16 - September - 2024

**Weitere Informationen finden Sie unter:**

[Link zur Website der EMA](#)

**PSUR outcome: Cefpodoxim**

**Veröffentlicht am:** 27 - September - 2024

**Weitere Informationen finden Sie unter:**

[https://www.basq.gv.at/fileadmin/redakteure/07\\_Unternehmen/PV-Mustertexte/ab\\_2023/240926\\_CL\\_PSUSA\\_Cefpodoxim\\_signiert.pdf](https://www.basq.gv.at/fileadmin/redakteure/07_Unternehmen/PV-Mustertexte/ab_2023/240926_CL_PSUSA_Cefpodoxim_signiert.pdf)

[Link zur Website der EMA](#)

## Humanarzneimittel - Schweiz

### **Neues Verordnungsrecht gilt ab 1. November 2024**

**Veröffentlicht am:** 16 - September - 2024

**Weitere Informationen finden Sie unter:**

<https://www.swissmedic.ch/swissmedic/de/home/news/mitteilungen/verordnungsrecht-ab-1-nov-2024.html>

### **Internationales Treffen des Permanent Forum on International Pharmaceutical Crime**

**Veröffentlicht am:** 17 - September - 2024

**Weitere Informationen finden Sie unter:**

<https://www.swissmedic.ch/swissmedic/de/home/news/mitteilungen/internationales-treffen-des-permanent-forum-on-international-pharmaceutical-crime.html>

### **Aufforderung zur Überprüfung altrechtlicher Produkte**

**Veröffentlicht am:** 18 - September - 2024

**Weitere Informationen finden Sie unter:**

<https://www.swissmedic.ch/swissmedic/de/home/medizinprodukte/uebersicht-medinprodukte/aufforderung-ueberpruefung-altrechtlicher-produkte.html>

### **Unvollständige Angaben auf perforierten Blistern**

**Veröffentlicht am:** 20 - September - 2024

**Weitere Informationen finden Sie unter:**

<https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/marktueberwachung/qualitaetsmaengel-und-charge Rueckrufe/unvollstaendige-angaben-auf-perforierten-blistern.html>

### **Go-live der SwissGMDP Datenbank**

**Veröffentlicht am:** 20 - September - 2024

**Weitere Informationen finden Sie unter:**

[https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/bewilligungen\\_zertifikate/betriebsbewilligungen/swissgmdp.html](https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/bewilligungen_zertifikate/betriebsbewilligungen/swissgmdp.html)

### **Aktualisierte Vorgabedokumente**

**Veröffentlicht am:** 24 - September - 2024

**Weitere Informationen finden Sie unter:**

[https://www.swissmedic.ch/swissmedic/de/home/news/updates/updated\\_documents/sept-2024.html](https://www.swissmedic.ch/swissmedic/de/home/news/updates/updated_documents/sept-2024.html)



## Fragen an das Netzwerk

**Falls Sie eine Frage haben, die Sie gerne in unserem Netzwerk diskutieren würden, senden Sie uns einfach eine E-Mail an [info-as@megra.org](mailto:info-as@megra.org) zur anonymen Publikation im nächsten Newsletter.\***

\*Bei der Beantwortung der Fragen handelt es sich um eine Zusammenfassung von persönlichen Meinungen und Erfahrungswerten der MEGRA Mitglieder mit keinem Anspruch auf Rechtssicherheit. Wir empfehlen zur Absicherung die Konsultation entsprechender zugrunde liegender Regularien.

- 1) Benötigt das Vereinigte Königreich auch nach der Einführung des Windsor Frameworks noch lineare Strichcodes oder reicht eine 2D Data Matrix Code auf den Faltpackungen aus?
- 2) Benötigt das Vereinigte Königreich eine Seriennummer in einem beliebigen Format?

Und nochmals der Aufruf zur Unterstützung der Masterarbeit:

Im Rahmen einer Masterthesis soll die geplante Abschaffung des Sunset Clauses per vorgeschlagener Reform des EU-Arzneimittelrechts von 2023 untersucht werden. Gerne würde ich neben meinem Standpunkt weitere Argumente der Industrie einbringen und möchte deshalb die MEGRA-Mitglieder um ihre Meinung konsultieren: Könnten Sie mir Ihre Sichtweise zu der Abschaffung des Sunset Clauses mitteilen?

# Veranstaltungen / Events – Behörden und andere Veranstalter

## Deutschland

**"The Product is the Process – Is it?" Manufacturing and Translation of ATMPs and Tissue- & Cell-based products**

**Ort:** Investitionsbank des Landes Brandenburg, Babelsberger Straße 21, 14473 Potsdam

**Termin:** 28 - November - 2024

**Weitere Informationen finden Sie unter:**

<https://www.pei.de/SharedDocs/veranstaltungen-events/DE/2024/2024-11-28-workshop-manufacturing-translation-atmp.html?nn=170994>

## Österreich

**BASG-Gespräch: Quality Day - Neuigkeiten aus dem Bereich Arzneimittelqualität**

**Ort:** Online via Zoom

**Termin:** 16 - Oktober - 2024

**Weitere Informationen finden Sie unter:**

<https://www.ages.at/ages/veranstaltungen/veranstaltungskalender/detail/basg-gespraech-quality-day-neuigkeiten-aus-dem-bereich-arzneimittelqualitaet-1>

## Schweiz

**Swissmedic Regulatory & Beyond 2024**

**Ort:** Kursaal Bern

**Termin:** 26 - November - 2024

**Weitere Informationen finden Sie unter:**

<https://rb-swissmedicevents.ch/>

## Europa

**2024 annual workshop of the European network of paediatric research at EMA (Enpr-EMA)**

**Where:** online and European Medicines Agency, Amsterdam, the Netherlands

**Date:** 02 - October - 2024

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/2024-annual-workshop-european-network-paediatric-research-ema-enpr-ema>



## Veranstaltungen / Events – Behörden und andere Veranstalter

### **SPOR and xEVMPD Stakeholder Engagement Webinars : SPOR Data Governance**

**Where:** online and European Medicines Agency, Amsterdam, the Netherlands

**Date:** 04 to 14 - October - 2024

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/spor-xevmpd-stakeholder-engagement-webinars-spor-data-governance>

### **CPhI Worldwide & CEP One-to-One Sessions**

**Where:** Milan, Italy

**Date:** 08 to 10 - October - 2024

**For more information, please refer to:**

<https://www.edqm.eu/en/cphi-worldwide-cep-one-to-one-sessions>

### **Scientific Symposium on Advanced Therapy Medicinal Products - ‘Contribution, evolution, revolution’**

**Where:** European Medicines Agency, Amsterdam, the Netherlands

**Date:** 10 - October - 2024

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/scientific-symposium-advanced-therapy-medicinal-products-contribution-evolution-revolution>

### **EDQM workshop: exploring a certification system for the validation of rapid microbiological methods**

**Where:** Strasbourg, France

**Date:** 15 to 16 - October - 2024

**For more information, please refer to:**

<https://www.edqm.eu/en/edqm-workshop-exploring-a-certification-system-for-the-validation-of-rapid-microbiological-methods->

### **Training webinar on Product Management Service (PMS) Product User Interface (PUI)**

**Where:** online

**Date:** 16 - October - 2024

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/training-webinar-product-management-service-pms-product-user-interface-pui>

### **EUHPP webinar: 25 years of breast cancer research: Past, present and future**

**Where:** online

**Date:** 16 - October - 2024

**For more information, please refer to:**

[https://health.ec.europa.eu/latest-updates/registration-open-euhpp-webinar-25-years-breast-cancer-research-past-present-and-future-16-october-2024-09-17\\_en](https://health.ec.europa.eu/latest-updates/registration-open-euhpp-webinar-25-years-breast-cancer-research-past-present-and-future-16-october-2024-09-17_en)

## Veranstaltungen / Events – Behörden und andere Veranstalter

### **Clinical Trials Information System (CTIS) bitesize talk: End of transition period and notifications including serious breach**

**Where:** online and European Medicines Agency, Amsterdam, the Netherlands

**Date:** 16 - October - 2024

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/clinical-trials-information-system-ctis-bitesize-talk-end-transition-period-notifications-including-serious-breach>

### **Clinical Trials Information System (CTIS): Information day**

**Where:** online and European Medicines Agency, Amsterdam, the Netherlands

**Date:** 17 - October - 2024

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/clinical-trials-information-system-ctis-information-day-0>

### **Small and medium-sized enterprises info day**

**Where:** European Medicines Agency, Amsterdam, the Netherlands

**Date:** 18 - October - 2024

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/small-medium-sized-enterprises-info-day>

### **ACT EU multi-stakeholder platform annual meeting**

**Where:** online and European Medicines Agency, Amsterdam, the Netherlands

**Date:** 22 - October - 2024

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/act-eu-multi-stakeholder-platform-annual-meeting>

### **eXtended EudraVigilance Medicinal Product Dictionary (XEVMPPD) training course**

**Where:** online

**Date:** 22 to 24 - October - 2024 and 18 to 20 - November - 2024

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/extended-eudravigilance-medicinal-product-dictionary-xevmpd-training-course-october-2024>

<https://www.ema.europa.eu/en/events/extended-eudravigilance-medicinal-product-dictionary-xevmpd-training-course-november-2024>

### **Q&A clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API)**

**Where:** online and European Medicines Agency, Amsterdam, the Netherlands

**Date:** 22 - October - 2024 and 29 - October - 2024

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/qa-clinic-product-management-service-pms-product-user-interface-pui-application-programming-interface-api-22-october-2024>

<https://www.ema.europa.eu/en/events/qa-clinic-product-management-service-pms-product-user-interface-pui-application-programming-interface-api-29-october-2024>

## Veranstaltungen / Events – Behörden und andere Veranstalter

### ***New fee regulation: webinar for human industry stakeholders***

***Where:*** online and European Medicines Agency, Amsterdam, the Netherlands

***Date:*** 24 - October - 2024

***For more information, please refer to:***

<https://www.ema.europa.eu/en/events/new-fee-regulation-webinar-human-industry-stakeholders>

### ***HMA/EMA multi-stakeholder workshop on Artificial Intelligence***

***Where:*** European Medicines Agency, Amsterdam, the Netherlands

***Date:*** 05 - November - 2024

***For more information, please refer to:***

<https://www.ema.europa.eu/en/events/hma-ema-multi-stakeholder-workshop-artificial-intelligence>

### ***Third European Medicines Agency (EMA) and European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) bilateral meeting***

***Where:*** European Medicines Agency, Amsterdam, the Netherlands

***Date:*** 07 - November - 2024

***For more information, please refer to:***

<https://www.ema.europa.eu/en/events/third-european-medicines-agency-ema-european-confederation-pharmaceutical-entrepreneurs-eucope-bilateral-meeting>

### ***Translating innovation into access for ATMPs: 3rd EU-Innovation network multi-stakeholder meeting***

***Where:*** online and Rome, Italy

***Date:*** 15 - November - 2024

***For more information, please refer to:***

<https://www.ema.europa.eu/en/events/translating-innovation-access-atmps-3rd-eu-innovation-network-multi-stakeholder-meeting>

### ***Clinical Trials Information System (CTIS): Walk-in clinic - November 2024***

***Where:*** online and European Medicines Agency, Amsterdam, the Netherlands

***Date:*** 20 - November - 2024

***For more information, please refer to:***

<https://www.ema.europa.eu/en/events/clinical-trials-information-system-ctis-walk-clinic-november-2024>

### ***Everything you've always wanted to know about the certification (CEP) procedure***

***Where:*** online

***Date:*** 21 - November - 2024

***For more information, please refer to:***

<https://www.edqm.eu/en/-webinar-cep-procedure>

## Veranstaltungen / Events – Behörden und andere Veranstalter

### ***EU Health Policy Platform Annual Meeting***

***Where:*** online

***Date:*** 26 - November - 2024

***For more information, please refer to:***

[https://health.ec.europa.eu/latest-updates/register-now-participate-onsite-or-online-eu-health-policy-platform-annual-meeting-26-november-and-2024-09-20\\_en](https://health.ec.europa.eu/latest-updates/register-now-participate-onsite-or-online-eu-health-policy-platform-annual-meeting-26-november-and-2024-09-20_en)

### ***Advancements in gene therapy: the European Pharmacopoeia's new approach***

***Where:*** online

***Date:*** 03 - December - 2024

***For more information, please refer to:***

<https://www.edqm.eu/en/advancements-in-gene-therapy-the-european-pharmacopoeia-s-new-approach>